期刊文献+

左西孟旦对顽固性心衰的疗效研究 被引量:3

Curative effect of Levosimendan in refractory heart failure and its effect on ventricular arrhythmia and inflammatory factor
下载PDF
导出
摘要 目的通过左西孟旦对顽固性心衰患者脑钠肽前体(pro-BNP)、心脏彩超左室射血分数(LVEF)及左室舒张末容积(LVEDV)、室性心律失常、炎症因子的影响,来观察研究左西孟旦治疗顽固性心衰患者的效果及其可能的作用机制。方法筛选出顽固性心衰的患者80人,随机分成两组,分别给予左西孟旦和米力农治疗,治疗前后分别测pro-BNP,LVEF,LVEDV,室性心律失常的次数及高敏C反映蛋白(hs-CRP),肿瘤坏死因子-a(TNF-a)。结果与对照组相比,经左西孟旦治疗后患者的pro-BNP水平、室性心律失常的次数显著下降,两组间LVEDV下降值无明显差距,左西孟旦组LVEF显著升高,同时hs-CRP、TNF-a也显著下降。结论左西孟旦治疗顽固性心衰优于传统正性肌力药物。 Objectives This study addressed to measure pro-brain natriuretic peptide( pro-BNP),left ventricular ejection fraction( LVEF),left ventricular end diastolic volume( LVEDV) and ventricular arrhythmia and inflammatory factor in patients with refractory heart failure,aims to observe the efficacy and action mechanism of Levosimendan. Methods Selected eighty patients with refractory heart failure,that divided into two groups randomly and received Levosimendan or Milrinone treatment respectively. Recorded the dates of pro-BNP,LVEF,LVEDV,hs-CRP,TNF-a and times of ventricular arrhythmia at pretherapy and post-treatment.Results Compared with control group,the levels of pro-BNP and times of ventricular arrhythmia in Levosimendan group were significantly lower. The decrease of LVEDV in the two groups were no gap. The date of LVEF% was higher than that in the Levosimendan group. The hs-CRP,TNF-a in Levosimendan group were significantly lower. Conclusions Levosimendan is better in treating refractory heart failure than that of traditional positive inotropic drug.
出处 《中国老年保健医学》 2015年第5期63-65,共3页 Chinese Journal of Geriatric Care
关键词 左西孟旦 顽固性心衰 心功能 室性心律失常 炎症因子 Levosimendan Refractory heart failure Cardiac function
  • 相关文献

参考文献10

  • 1董颖,王礼琛.新型抗心衰药物——钙增敏剂作用机制的研究进展[J].中国新药杂志,2004,13(3):201-205. 被引量:4
  • 2Kopustinskiene DM, Pollesello P, Saris NE. Levosirnendan is a mito- chondrial K channel opener [ J ]. European Journal of Pharmacology, 2001,428:311 - 314.
  • 3Kersten JR, Montgomery MW, Pagel PS,et al. Levosimendan a new positive inotropic drug, decreases myocardial infarct size via activation of K channel[ J]. Anesth Analg, 2000, 90:5 - 11.
  • 4Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent [ J ]. Anestbesiolng, 2006, 104:556 - 569.
  • 5Cleland JG, Nikitin N, McGo wan J. Levosimendan: first in a new class of in odilator for acute and chronic severe heart failure[ J]. Expert Rev Cardiovasc Ther, 2004,1:9 - 19.
  • 6Adamopoulos, Parissis JT, Iliodromitis EK, et al. Effects of Levosi- mendan Versus Dobuta mine on Inflammatory and Apopotie Path ways in Acutely Decompensated Chronic Heart Failure [ J ]. Am J Cardio, 2006,98 ( 1 ) : 102 - 106.
  • 7Li JJ. Rapid effects on lipid profile and C-reactive protein by simvasta- tin in patients with hypercholesterolemia[ J]. Clin clin Cardiol, 2003, 26:472 - 476.
  • 8盖延红,蔡尚郎.急性冠脉综合征患者BNP、超敏CRP与LP(a)水平的相关研究[D].青岛大学,2008:21-24.
  • 9孟竹,崔国方,付丽娜,李玉耕.冠状动脉狭窄患者NT-proBNP/hs-CRP与心脏功能的相关性研究[J].中国循证心血管医学杂志,2012,4(6):524-526. 被引量:13
  • 10Bets DM. Cardiac excitation-contraction coupling[ J]. Nature, 2002, 415(6868) :198 -205.

二级参考文献53

  • 1庄晓峰,许朝祥,杜心清.纤维蛋白原与超敏C-反应蛋白、冠状动脉病变的相关性[J].福建医科大学学报,2006,40(2):150-153. 被引量:35
  • 2Takahashi R, Hassan TMA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium[J]. J Cardiouasc Pharmacol,2000,36( 1 ) : 118 - 125.
  • 3Endoh M. Mechanisms of action of novel cardiotonic agents[J]. J Cardiovasc Pharmacol, 2002,40 ( 3 ) : 323 - 338.
  • 4Sato S, Hassan Talukoler MA,Sugawara H, et al. Effects of levosimendan on myocardial contractility and Ca^2+ transients in aequorin-loaded right-ventricular muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit[J]. J Mol Cell Cardiol ,1998,30(8):1115-1128.
  • 5Brixius K, Mehlhorn U, Bloch W, et al. Different effect of the Ca^2+ sensitizer EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium[J]. J Pharmacol Eap Ther ,2000.295(3):1284- 1290.
  • 6Pan BS, Johnson RG. Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C[J]. J Biol Chem, 1996,271(2) :817 - 823.
  • 7Duncker DJ, Haitsma DB, Liem DA, et al. Beneficial effects of the Ca^2+ sensitizer EMD 57033 in exercising pigs with infraction-induced chronic left ventricular dysfunction[J]. Br J Pharmacol,2001,134(3) :553 - 562.
  • 8Kitada Y. MCI-154:a second generation Ca^2+ sensitizer that does not impair relaxation a novel approach to the treatment of heart failure[J ]. Cardiovasc Drug Rev ,2000,18(4) :271 - 283.
  • 9Doggell SA,Brown L,Castaner J, et al. EMD 57033[J]. Drugs Fur,2002,27(1) : 14 - 20.
  • 10Toiler WG, Pagel PS, Kersten JR, et al. Levosimendan [J].Drugs Fut,2000,25(6):563- 568.

共引文献15

同被引文献33

  • 1Roger V L. Epidemiology of heart failure [J]. Circ Res, 2013, 113(6): 646-659.
  • 2Nieminen M S, Fruhwald S, Heunks L, et al. Levosimendan: current data, clinical use and future development [J]. Heart Lung Vessels, 2013, 5(4): 227-245.
  • 3Bonios M J, Terrovitis J V, Drakos S G~ et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure [J]. lnt J Cardiol, 2012, 159(3): 225-229.
  • 4Malfatto G, Della Rosa F, Villani A, et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular fimction, neurohormonal balance, and one-year survival [J]. J Cardiovasc Pharmacol, 2012, 60(5): 450-455.
  • 5Altenberger J, Parissis J T, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial [J]. Eur J Heart Fail, 2014, 16(8): 898-906.
  • 6Rauch H, Motsch J, B6ttiger B W. Newer approaches to the pharmacological management of heart failure [J]. Curr Opin Anaesthesiol, 2006, 19(1): 75-81.
  • 7Yeo P S. Levosimendan in end-stage heart failure [J]. JACC Heart Fail, 2013, 1(4): 365.
  • 8Nieminen M S, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus [J]. Int J Cardiol, 2014, 174(2): 360-367.
  • 9Silvetti S, Greco T, Di Prima A L, et al. Intermittent levosimendan improves mid-term survival in chronicheart failure patients: meta-analysis of randomised trials [J]. Clin Res Cardiol, 103 (7) (2014) 505-513.
  • 10Vanderheyden M, Vrints C, Verstreken S, et al. B-typenatriuretie peptide as a marker of heart failure: new insights from biochemistry and clinical implications [J]. BiomarkMed, 2010, 4(2): 315-320.

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部